Charles River Laboratories International, Inc. $CRL Shares Acquired by Assetmark Inc.

Assetmark Inc. lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 20.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,143 shares of the medical research company’s stock after buying an additional 6,301 shares during the period. Assetmark Inc.’s holdings in Charles River Laboratories International were worth $5,811,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. Principal Financial Group Inc. lifted its stake in Charles River Laboratories International by 84.5% in the 3rd quarter. Principal Financial Group Inc. now owns 104,719 shares of the medical research company’s stock worth $16,384,000 after purchasing an additional 47,954 shares in the last quarter. Penserra Capital Management LLC purchased a new stake in shares of Charles River Laboratories International in the third quarter valued at approximately $533,000. Invesco Ltd. increased its holdings in shares of Charles River Laboratories International by 11.6% in the second quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company’s stock valued at $187,712,000 after purchasing an additional 128,785 shares during the last quarter. Cooke & Bieler LP increased its holdings in shares of Charles River Laboratories International by 0.9% in the third quarter. Cooke & Bieler LP now owns 603,877 shares of the medical research company’s stock valued at $94,483,000 after purchasing an additional 5,100 shares during the last quarter. Finally, Madison Asset Management LLC purchased a new position in Charles River Laboratories International during the third quarter worth approximately $1,935,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Robert W. Baird set a $224.00 target price on Charles River Laboratories International in a report on Friday, January 9th. TD Cowen reissued a “buy” rating on shares of Charles River Laboratories International in a report on Thursday, January 22nd. Wall Street Zen raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. Barclays increased their price target on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Finally, Argus set a $200.00 price target on shares of Charles River Laboratories International in a research report on Monday, November 17th. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average price target of $209.46.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $158.06 on Wednesday. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $228.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37. The company has a 50 day moving average price of $202.19 and a 200 day moving average price of $179.58. The stock has a market capitalization of $7.78 billion, a P/E ratio of -101.32, a PEG ratio of 4.88 and a beta of 1.63.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.